ERRATUM
Volume 62, no. 6, e02603-17, 2018. https://doi.org/10.1128/AAC.02603-17. References list: the DOI given for reference 8 is incorrect. It should be https://doi.org/10.1128/AAC.01627-16.
. 2019 Mar 27;63(4):e00333-19. doi: 10.1128/AAC.00333-19
Erratum for Lakota et al., “Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data”
Elizabeth A Lakota
a, Voon Ong
b, Shawn Flanagan
b, Christopher M Rubino
a
Elizabeth A Lakota
aInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA
Find articles by Elizabeth A Lakota
Christopher M Rubino
aInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA
Find articles by Christopher M Rubino
aInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA
bCidara Therapeutics, San Diego, California, USA
Citation Lakota EA, Ong V, Flanagan S, Rubino CM. 2019. Erratum for Lakota et al., “Population pharmacokinetic analyses for rezafungin (CD101) efficacy using phase 1 data.” Antimicrob Agents Chemother 63:e00333-19. https://doi.org/10.1128/AAC.00333-19.
Collection date 2019 Apr.
PMCID: PMC6437527 PMID: 30917976
This corrects the article "Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data" in volume 62, e02603-17.